![](https://cellvax-pharma.com/wp-content/uploads/2018/01/Cancer-preclinical-research-Cellvax.jpg)
ONCOLOGY
Cancer still remains a major public health problem in the world. Therefore, the development of new therapeutic strategies is highly awaited. Cellvax conducts preclinical studies.
![](https://cellvax-pharma.com/wp-content/uploads/2018/01/Osteoarthritis-prelinical-research-Cellvax.jpg)
OSTEOARTHRITIS
Osteoarthritis affects large number of population including young adults. Several relevant animal models are available at Cellvax to validate novel treatments.
![](https://cellvax-pharma.com/wp-content/uploads/2017/08/ToxicityPK-Cellvax-1.jpg)
Toxicity PK / Biodistributions studies
A complete toxicity experiment can be proposed at Cellvax in both rodent and nonrodents. In order to understand the pharmacokinetics (PK) of your innovating drugs, we propose a bio-distribution and PK studies in animal models
Company Office
Cellvax, SAS
Villejuif Bio Park
1, mail du Professeur Georges Mathé
94800, Villejuif
France
(GPS address: 10 rue Guy Moquet 94800 Villejuif France)
Tel: + 33 (0) 9 52 30 26 20
Cell: +33 (0) 6 71 43 47 51
Fax: + 33 (0) 9 52 30 26 20
E-mail: contact@cellvax-pharma.com